Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Swanson

Showing results (151-160 of 176) with videos related to

Pageof 18
Sort By:
Journal of Medicinal Chemistry|September 1, 1990
Dihydropyrimidine calcium channel blockers. 2. 3-substituted-4-aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic acid esters as potent mimics of dihydropyridinesK S Atwal, G C Rovnyak, S D Kimball, et al.
Regulatory Peptides|August 13, 1992
Discovery of a distinct binding site for angiotensin II (3-8), a putative angiotensin IV receptorG N Swanson, J M Hanesworth, M F Sardinia, et al.
Antimicrobial Agents and Chemotherapy|October 23, 2013
Novel antifungal drug discovery based on targeting pathways regulating the fungus-conserved Upc2 transcription factorChristina Gallo-Ebert, Melissa Donigan, Ilana L Stroke, et al.
Brain Research|June 26, 1992
Identification of an AII(3-8) [AIV] binding site in guinea pig hippocampusJ W Harding, V I Cook, A V Miller-Wing, et al.
The Annals of Otology, Rhinology, and Laryngology|June 16, 2023
Effect of Dupilumab on Type 2 Biomarkers in Chronic Rhinosinusitis With Nasal Polyps: SINUS-52 Study ResultsClaus Bachert, Tanya M Laidlaw, Seong H Cho, et al.
Implementation Science Communications|August 19, 2025
Beyond the surface of capacity building: a mixed-methods study of the core functions and forms of dissemination and implementation science consultationsKera N Swanson, Nicole A Stadnick, Gregory A Aarons, et al.
Allergy|November 30, 2018
Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposisKarin Jonstam, Brian N Swanson, Leda P Mannent, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|May 26, 2021
Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseasesJennifer D Hamilton, Sivan Harel, Brian N Swanson, et al.
Bioorganic & Medicinal Chemistry Letters|August 20, 2010
Identification and hit-to-lead optimization of a novel class of CB1 antagonistsJeffrey J Letourneau, Patrick Jokiel, John Olson, et al.
Clinical Pharmacology in Drug Development|April 30, 2020
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult SubjectsZhaoyang Li, Allen Radin, Meng Li, et al.
Pageof 18

Showing results (151-160 of 176) with videos related to

Sort By:
Pageof 18
Journal of Medicinal Chemistry|September 1, 1990
Dihydropyrimidine calcium channel blockers. 2. 3-substituted-4-aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic acid esters as potent mimics of dihydropyridinesK S Atwal, G C Rovnyak, S D Kimball, et al.
Regulatory Peptides|August 13, 1992
Discovery of a distinct binding site for angiotensin II (3-8), a putative angiotensin IV receptorG N Swanson, J M Hanesworth, M F Sardinia, et al.
Antimicrobial Agents and Chemotherapy|October 23, 2013
Novel antifungal drug discovery based on targeting pathways regulating the fungus-conserved Upc2 transcription factorChristina Gallo-Ebert, Melissa Donigan, Ilana L Stroke, et al.
Brain Research|June 26, 1992
Identification of an AII(3-8) [AIV] binding site in guinea pig hippocampusJ W Harding, V I Cook, A V Miller-Wing, et al.
The Annals of Otology, Rhinology, and Laryngology|June 16, 2023
Effect of Dupilumab on Type 2 Biomarkers in Chronic Rhinosinusitis With Nasal Polyps: SINUS-52 Study ResultsClaus Bachert, Tanya M Laidlaw, Seong H Cho, et al.
Implementation Science Communications|August 19, 2025
Beyond the surface of capacity building: a mixed-methods study of the core functions and forms of dissemination and implementation science consultationsKera N Swanson, Nicole A Stadnick, Gregory A Aarons, et al.
Allergy|November 30, 2018
Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposisKarin Jonstam, Brian N Swanson, Leda P Mannent, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|May 26, 2021
Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseasesJennifer D Hamilton, Sivan Harel, Brian N Swanson, et al.
Bioorganic & Medicinal Chemistry Letters|August 20, 2010
Identification and hit-to-lead optimization of a novel class of CB1 antagonistsJeffrey J Letourneau, Patrick Jokiel, John Olson, et al.
Clinical Pharmacology in Drug Development|April 30, 2020
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult SubjectsZhaoyang Li, Allen Radin, Meng Li, et al.
Pageof 18